April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Management of primary intraocular lymphoma (PIOL): results from the prospective German PIOL Registry (PIOL-R)
Author Affiliations & Notes
  • Uwe Pleyer
    Department of Ophthalmology, Charite, Berlin, Germany
    Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • Agnieszka Korfel
    Department of Ophthalmology, Charite, Berlin, Germany
    Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • Martina Herwig
    3Department of Ophthalmology, University of, Bonn, Germany
  • Rainer Guthoff
    4Department of Ophthalmology, University of, Düsseldorf, Germany
  • Matthias Lüke
    5Department of Ophthalmology, University of, Lübeck, Germany
  • Tobias Meyer-ter-Vehn
    6Department of Ophthalmology, University of, Würzburg, Germany
  • Antonia M Joussen
    Department of Ophthalmology, Charite, Berlin, Germany
    Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • Michael Böhm
    Department of Ophthalmology, University of, Münster, Germany
  • Friederike Mackensen
    8Department of Ophthalmology, University of, Heidelberg, Germany
  • Kristoph Jahnke
    Department of Ophthalmology, Charite, Berlin, Germany
    Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • Footnotes
    Commercial Relationships Uwe Pleyer, None; Agnieszka Korfel, None; Martina Herwig, None; Rainer Guthoff, None; Matthias Lüke, None; Tobias Meyer-ter-Vehn, None; Antonia Joussen, None; Michael Böhm, None; Friederike Mackensen, None; Kristoph Jahnke, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 88. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Uwe Pleyer, Agnieszka Korfel, Martina Herwig, Rainer Guthoff, Matthias Lüke, Tobias Meyer-ter-Vehn, Antonia M Joussen, Michael Böhm, Friederike Mackensen, Kristoph Jahnke, ; Management of primary intraocular lymphoma (PIOL): results from the prospective German PIOL Registry (PIOL-R). Invest. Ophthalmol. Vis. Sci. 2014;55(13):88.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Primary intraocular lymphoma (PIOL) is a very rare disorder, and the optimal treatment is yet to be defined. Here, we report on clinical characteristics, treatment and outcome of patients with PIOL enrolled in the prospective German PIOL registry (PIOL-R).

Methods: Patient data in this prospective, non-interventional multicenter study were compiled by standardized questionnaires sent to Ophthalmology and Hematology/Oncology departments in Germany. Only immunocompetent patients were eligible and diagnosis had to be confirmed histologically or cytologically.

Results: Twenty patients (12 female, median age 67 years, median Karnofsky performance status 90%) were included between August 2008 and August 2013. Median follow-up was 20.2 months. Median time from onset of symptoms to PIOL diagnosis was 5 (range, 1-12) months. Diffuse large B-cell histology was found in all patients. Eleven patients had prior (n=3), concomitant (n=3), and/or subsequent (n=5) parenchymal brain involvement. First-line treatment included high-dose Methotrexate (MTX)- or Ifosfamide-based systemic chemotherapy with or without Rituximab in 17 (including high-dose chemotherapy [HDCT] with autologous stem cell transplantation [ASCT] in 2), intraocular (i.o.) chemotherapy with MTX (n=2) and/or Rituximab (n=8) in 9, and ocular radiation in one patient(s). Two patients received prophylactic intrathecal treatment with MTX but none had whole-brain irradiation. The PIOL remission rate was 100% with complete remission in 14/18 evaluable patients and partial remission in 4 patients. Median progression-free survival was 8.1 months. Overall survival has not yet been reached. Relapses were located in the brain (n=8), eye (n=1), eye/brain (n=3) and eye/meninges (n=1) and were treated with systemic chemotherapy in 10 (including HDCT with ASCT in 3), systemic and i.o. chemotherapy in 1, and whole brain/spine radiotherapy in 2 patient(s).

Conclusions: Although the awareness of PIOL and diagnostic possibilities have improved over the past two decades, time from symptom presentation to diagnosis seems to remain at previously reported levels. There appears to be a shift from local ocular treatments and radiation to systemic therapy as compared to anecdotal data with promising response and survival rates. However, relapse rates remain high.

Keywords: 744 tumors • 745 uvea • 452 choroid  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×